Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASolve 301: daraxonrasib vs docetaxel in previously treated RAS-mutated NSCLC
NCT06881784Phase 3Recruiting
- Sponsor
- Revolution Medicines
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of daraxonrasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Revolution Medicines. Primary endpoints: Progression-Free Survival at 4 years and Overall Survival at 4 years. Started May 2025; status: recruiting.
02
Drugs
daraxonrasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06881784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06881784.